Eli Lilly's popular weight-loss drug Zepbound outperformed Danish drugmaker Novo Nordisk's Wegovy in a clinical trial, ...
Given the strong demand expected for Eli Lilly's (NYSE:LLY) weight loss treatment Zepbound (tirzepatide) in the UK, the ...
Those treated with tirzepatide, a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist, lost on ...
Eli Lilly (NYSE:LLY) has been making headlines recently with its weight-loss drug Zepbound (tirzepatide). Eli Lilly ...
One of Eli Lilly's potential competitors in the weight loss market just reported unimpressive trial results. The company ...
Adults taking Eli Lilly's Zepbound lost 47% more weight on average than those on Novo Nordisk's Wegovy, Lilly reported from ...
Drugmaker Eli Lilly and Co. will invest $3 billion and add 750 employees in Kenosha County as the company expands a plant it ...
Eli Lilly (LLY) plans to boost production of its popular diabetes and weight-loss medications with a $3B expansion of its ...
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market ...